# Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation

## TL;DR

Two non-small cell lung cancer patients with MET amplification and EGFR mutation responded well to a combination therapy of Savolitinib and EGFR-TKI.

## Contribution

This case report is the first to show the efficacy of dual-target therapy in NSCLC patients with primary MET amplification and EGFR mutation.

## Key findings

- Two NSCLC patients achieved approximately 5 months of progression-free survival with T+S therapy.
- T+S therapy showed acceptable safety and encouraging antitumor effects in this rare patient subgroup.
- Genetic testing at first diagnosis is emphasized for optimal targeted therapy selection.

## Abstract

Lung cancer is the leading cause of cancer death, accounting for one-third of all cancer deaths worldwide. The MET (c-MET) gene, as one of the therapeutic target spots of NSCLC, has become increasingly more important. MET amplification/overexpression was divided into primary (intrinsic) and secondary (acquired). Studies indicated that the combination of Osimertinib and Savolitinib was safe and showed promising antitumor effect in NSCLC patients with secondary MET amplification after EGFR mutations. However, NSCLC patients with primary MET amplification/overexpression and EGFR mutations are rare in clinics, and the efficacy of dual-target therapy combined with EGFR-TKI and Savolitinib for them has not been studied yet. Here, we reported two NSCLC patients with primary MET amplification/overexpression and EGFR mutation, who benefited from T+S therapy (the dual-target therapy of EGFR-TKI plus Savolitinib) and achieved a progression-free survival (PFS) of approximately 5 months. The two cases indicated that T+S therapy has an acceptable safety profile and encouraging antitumor efficacy in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation. Meanwhile, the observation stresses the importance of genetic testing, and the MET gene needs to be detected at first diagnosis for the best choice of targeted therapies.